Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
C-Rad AB (publ) (CRAD-B.ST)
Uppsala, AB, SE
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking; and cAccessory, which automates the registration and validation of treatment accessories. Further, it provides SmartPhantom RT, a device that allows automatic adjustment and alignment of fixed lasers with motorization; StaticPhantom, a set-up used to visually verify the precision of the alignment of lasers; high impact technology motorized system, a laser positioning system; HIT Single Diode; and HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +4.24% | +28.36% | +23.96% | +1.47% | +7.84% | +9.21% | +8.35% | -40.59% | +295.40% | +141.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-5.8% Q1'26: -11.9% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-81.4% Q1'26: +237.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+14.0% Q1'26: -26.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+10.2% Q1'26: +11.5% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+15.3% ★ Q1'26: +16.8% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.34× ★ Q1'26: 0.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
66.16M
est: 70.96M (-6.8%)
|
82.65M
est: 85.01M (-2.8%)
|
133.13M
est: 70.96M (+87.6%)
|
190.11M
est: 85.01M (+123.6%)
|
205.39M
est: 107.06M (+91.9%)
|
221.63M
est: 134.42M (+64.9%)
|
261.15M
est: 265.47M (-1.6%)
|
301.33M
est: 297.14M (+1.4%)
|
424.62M
est: 497.02M (-14.6%)
|
469.00M
est: 477.71M (-1.8%)
|
441.90M
est: 455.92M (-3.1%)
|
455.40M
455.40M – 455.40M
-0.1% YoY
|
505.30M
505.30M – 505.30M
+11.0% YoY
|
558.30M
531.18M – 585.42M
+10.5% YoY
|
| EBITDA |
-14.82M
est: 9.62M (-254.1%)
|
-24.46M
est: 11.53M (-312.2%)
|
-5.48M
est: 9.62M (-156.9%)
|
3.35M
est: 11.53M (-70.9%)
|
-5.11M
est: 14.51M (-135.2%)
|
26.15M
est: 18.22M (+43.5%)
|
45.71M
est: 35.99M (+27.0%)
|
27.35M
est: 40.29M (-32.1%)
|
48.90M
est: 68.09M (-28.2%)
|
83.91M
est: 65.45M (+28.2%)
|
55.30M
est: 62.46M (-11.5%)
|
62.39M
62.39M – 62.39M
-0.1% YoY
|
69.23M
69.23M – 69.23M
+11.0% YoY
|
76.49M
72.77M – 80.21M
+10.5% YoY
|
| EBIT |
-20.35M
est: 7.98M (-354.9%)
|
-30.45M
est: 9.56M (-418.4%)
|
-10.01M
est: 7.98M (-225.5%)
|
1.13M
est: 9.56M (-88.2%)
|
-9.85M
est: 12.04M (-181.8%)
|
17.12M
est: 15.12M (+13.2%)
|
35.91M
est: 29.86M (+20.3%)
|
21.76M
est: 33.42M (-34.9%)
|
44.31M
est: 58.35M (-24.1%)
|
80.06M
est: 56.08M (+42.8%)
|
45.00M
est: 53.52M (-15.9%)
|
53.46M
53.46M – 53.46M
-0.1% YoY
|
59.32M
59.32M – 59.32M
+11.0% YoY
|
65.54M
62.36M – 68.72M
+10.5% YoY
|
| Net Income |
-21.18M
est: -10.13M (-109.2%)
|
-31.21M
est: -36.54M (+14.6%)
|
-10.91M
est: -10.13M (-7.7%)
|
21.19M
est: -36.54M (+158.0%)
|
-13.80M
est: 5.16M (-367.3%)
|
14.37M
est: 18.94M (-24.2%)
|
25.10M
est: 27.21M (-7.8%)
|
7.48M
est: 17.61M (-57.5%)
|
35.53M
est: 53.43M (-33.5%)
|
56.45M
est: 61.31M (-7.9%)
|
10.50M
est: 31.98M (-67.2%)
|
52.50M
52.50M – 52.50M
+64.2% YoY
|
73.84M
73.84M – 73.84M
+40.6% YoY
|
93.82M
93.82M – 93.82M
+27.1% YoY
|
| SGA |
26.63M
est: 21.48M (+24.0%)
|
33.68M
est: 25.73M (+30.9%)
|
36.46M
est: 21.48M (+69.8%)
|
45.61M
est: 25.73M (+77.3%)
|
52.60M
est: 32.40M (+62.4%)
|
44.33M
est: 40.68M (+9.0%)
|
52.48M
est: 80.34M (-34.7%)
|
179.11M
est: 89.93M (+99.2%)
|
1.0K
est: 130.54M (-100.0%)
|
242.88M
est: 125.47M (+93.6%)
|
—
est: 119.74M (-100.0%)
|
119.61M
119.61M – 119.61M
-0.1% YoY
|
132.71M
132.71M – 132.71M
+11.0% YoY
|
146.63M
139.51M – 153.76M
+10.5% YoY
|
| EPS |
-0.99
est: -0.30 (-230.7%)
|
-1.21
est: -1.08 (-12.0%)
|
-0.37
est: -0.30 (-23.6%)
|
0.69
est: -1.08 (+163.9%)
|
-0.45
est: 0.15 (-394.9%)
|
0.43
est: 0.56 (-23.2%)
|
0.74
est: 0.80 (-8.0%)
|
0.22
est: 0.52 (-57.7%)
|
1.05
est: 1.58 (-33.4%)
|
1.67
est: 1.81 (-7.7%)
|
0.31
est: 0.94 (-67.2%)
|
1.55
1.55 – 1.55
+64.2% YoY
|
2.18
2.18 – 2.18
+40.6% YoY
|
2.77
2.77 – 2.77
+27.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Linda Frölén | Chief Financial Officer | 3M | female |
| Johan Danielsson | Deputy Chief Executive Officer & Vice President of Global Services | 2M | male |
| Eeva-Liisa Karjalainen | Chief Product & Technology Officer | — | female |
| Hakan Axelsson | Chief Operating Officer | — | male |
| Ivan Astralaga | President of Sales Americas | — | male |
| Lina Johansson | Head of Human Resources | — | female |
| Tomas Blomquist | Chief Executive Officer | — | male |
| Vincent Tallier | President Sales EMEA & Head of Global Marketing | — | male |
| Andreas Juhlin | Chief Commercial Officer | — | male |
| Xiaodong Wang | President of Sales Greater APAC | — | male |
| Basak Karakus | Executive for Global Digital Marketing | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRAD-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
